- Home
- MODV vs ATOS Comparison
MODV vs ATOS Comparison
Compare MODV & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODV
- ATOS
- Stock Information
- Founded
- MODV 1996
- ATOS 2009
- Country
- MODV United States
- ATOS United States
- Employees
- MODV N/A
- ATOS N/A
- Industry
- MODV Transportation Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- MODV Consumer Discretionary
- ATOS Health Care
- Exchange
- MODV Nasdaq
- ATOS Nasdaq
- Market Cap
- MODV 172.6M
- ATOS 174.8M
- IPO Year
- MODV N/A
- ATOS 2012
- Fundamental
- Price
- MODV $16.84
- ATOS $1.37
- Analyst Decision
- MODV Buy
- ATOS Strong Buy
- Analyst Count
- MODV 4
- ATOS 3
- Target Price
- MODV $27.25
- ATOS $6.75
- AVG Volume (30 Days)
- MODV 257.6K
- ATOS 540.1K
- Earning Date
- MODV 11-06-2024
- ATOS 11-12-2024
- Dividend Yield
- MODV N/A
- ATOS N/A
- EPS Growth
- MODV N/A
- ATOS N/A
- EPS
- MODV N/A
- ATOS N/A
- Revenue
- MODV $2,787,619,000.00
- ATOS N/A
- Revenue This Year
- MODV $4.32
- ATOS N/A
- Revenue Next Year
- MODV $7.14
- ATOS N/A
- P/E Ratio
- MODV N/A
- ATOS N/A
- Revenue Growth
- MODV 3.16
- ATOS N/A
- 52 Week Low
- MODV $11.00
- ATOS $0.63
- 52 Week High
- MODV $52.33
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- MODV 52.63
- ATOS 43.45
- Support Level
- MODV $15.34
- ATOS $1.36
- Resistance Level
- MODV $18.78
- ATOS $1.66
- Average True Range (ATR)
- MODV 1.11
- ATOS 0.08
- MACD
- MODV 0.24
- ATOS 0.00
- Stochastic Oscillator
- MODV 55.81
- ATOS 6.45
About MODV ModivCare Inc.
ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. The company is also a provider of non-emergency medical transportation, or NEMT, personal care, and remote patient monitoring, or RPM, solutions, which serve similar, highly vulnerable patient populations. Its operating segment includes NEMT, Personal Care, and Remote Patient Monitoring. The company generates maximum revenue from the NEMT segment.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.